We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01574430
First Posted: April 10, 2012
Last Update Posted: August 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mingwei Zhao, Peking University People's Hospital
  Purpose
The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.

Condition Intervention Phase
Central Serous Chorioretinopathy Procedure: PDT Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy

Resource links provided by NLM:


Further study details as provided by Mingwei Zhao, Peking University People's Hospital:

Primary Outcome Measures:
  • Change from baseline in BCVA [ Time Frame: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year ]

Secondary Outcome Measures:
  • Leakage at RPE level in FA [ Time Frame: 1 week ]
  • Change from baseline in central retinal thickness [ Time Frame: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year ]
  • The incidence rate of adverse event [ Time Frame: 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year ]

Estimated Enrollment: 131
Study Start Date: December 2010
Study Completion Date: December 2014
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 50% dose PDT
patients in this group was given 50% verteporfin dose PDT
Procedure: PDT
30% or 50% verteporfin dose PDT was given to patients with CSC
Other Name: photodynamic therapy
Experimental: 30% dose PDT
patients in this group was given 30% verteporfin dose PDT
Procedure: PDT
30% or 50% verteporfin dose PDT was given to patients with CSC
Other Name: photodynamic therapy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with CSC
  • patients signed the ICF
  • patients with course of CSC less than 6 months
  • patients did not undertake any treatment for CSC

Exclusion Criteria:

  • patients with porphyria
  • patients allergic to verteporfin
  • pregnant or nursing women
  • poor patients compliance
  • sever liver dysfunction
  • dioptric media opacities which make it difficult to exam fundus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01574430


Locations
China, Beijing
People's Hospital of Peking University
Beijing, Beijing, China, 100044
Sponsors and Collaborators
Peking University People's Hospital
Investigators
Study Director: Mingwei Zhao, M.D People's Hospital of Peking University
Principal Investigator: Youxin Chen, M.D Peking Union Medical College
Principal Investigator: Feng Zhang, M.D Beijing Tongren Hospital of Capital Medical University
Principal Investigator: Hong Dai, M.D Beijing Hospital
Study Chair: Xiaoxin Li, M.D People's Hospital of Peking University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mingwei Zhao, Dr., Peking University People's Hospital
ClinicalTrials.gov Identifier: NCT01574430     History of Changes
Other Study ID Numbers: PDTCSC-CHINA
First Submitted: April 8, 2012
First Posted: April 10, 2012
Last Update Posted: August 16, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Verteporfin
Photosensitizing Agents
Dermatologic Agents